Content about Bacterial vaginosis

March 26, 2014

Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.

DUBLIN and LAVAL, Quebec — Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel.

The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina. It's the most common vaginal infection in women ages 15 years to 44 years. Metronidazole 1.3% provides a single-dose treatment that is packaged in a pre-filled disposable applicator.

October 22, 2013

The Food and Drug Administration has approved a new generic drug for treating bacterial and protozoan infections, according to the agency.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new generic drug for treating bacterial and protozoan infections, according to the agency.

The FDA approved a generic version of Mission Pharmacal's Tindamax (tinidazole) made by Unique Pharmaceuticals. The drug is a tablet in the 250-mg and 500-mg strengths.

Tindamax is used to treat bacterial vaginosis, trichomoniasis and giardiasis. The drug has annual sales of about $16.2 million, according to IMS Health.

 

August 5, 2013

A new treatment for bacterial infections of the vagina is now available, the drug's manufacturer said.

ST. LOUIS — A new treatment for bacterial infections of the vagina is now available, the drug's manufacturer said Monday.

K-V Pharmaceutical Co. subsidiary Ther-Rx Corp. announced the availability of Clindesse (clindamycin phosphate), saying wholesalers have ordered and received it and are distributing it to retail pharmacies. The drug is used to treat bacterial vaginosis in women who are not pregnant. BV results from an overgrowth of several bacterial species and is the most common vaginal infection in women of childbearing age.

May 1, 2013

Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.

PARSIPPANY, N.J. — Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said Wednesday.

Actavis Specialty Brands' acquisition of Valeant's metronidazole vaginal gel is in the 1.3% strength. The deal includes an upfront payment, milestone payments and royalties for the first three years after the drug is commercialized. Actavis hopes to market the drug as early as the middle of next year.

January 31, 2013

Research has shown that 3-in-4 women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced, citing an independent survey commissioned for Monistat.

TREVOSE, Pa. — Research has shown that three in four women will experience candidiasis, more commonly known as a vaginal yeast infection, and 67% are embarrassed by it, Insight Pharmaceuticals announced Wednesday, citing an independent survey commissioned for Monistat.

March 8, 2010

Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that...

JACKSON, Wis. Lake Consumer Products last week launched vH essentials BV treatment, a homeopathic vaginal tablet that provides relief from the odor, discharge and discomfort often associated with bacterial vaginosis.

According to the company, vH essentials BV treatment is the first over-the-counter BV symptom treatment product to be widely distributed through retail.